X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1104) 1104
Publication (123) 123
Book Review (10) 10
Magazine Article (3) 3
Conference Proceeding (2) 2
Book Chapter (1) 1
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (909) 909
male (624) 624
quinoxalines - adverse effects (581) 581
index medicus (528) 528
female (527) 527
quinoxalines - therapeutic use (478) 478
varenicline (442) 442
middle aged (398) 398
adult (347) 347
quinoxalines - administration & dosage (316) 316
benzazepines - adverse effects (294) 294
aged (285) 285
animals (275) 275
smoking cessation - methods (268) 268
benzazepines - therapeutic use (259) 259
brimonidine tartrate (259) 259
treatment outcome (257) 257
pharmacology & pharmacy (221) 221
quinoxalines - pharmacology (211) 211
smoking cessation (208) 208
nicotinic agonists - adverse effects (202) 202
nicotinic agonists - therapeutic use (182) 182
receptor partial agonist (159) 159
double-blind method (151) 151
ophthalmology (146) 146
intraocular pressure - drug effects (144) 144
sustained-release bupropion (133) 133
efficacy (126) 126
safety (116) 116
glaucoma (113) 113
rats (112) 112
dose-response relationship, drug (110) 110
brimonidine (109) 109
medicine, general & internal (108) 108
benzazepines - administration & dosage (105) 105
smoking (105) 105
aged, 80 and over (103) 103
ocular hypertension - drug therapy (100) 100
drug therapy, combination (98) 98
glaucoma, open-angle - drug therapy (94) 94
smoking-cessation (94) 94
randomized controlled-trial (93) 93
young adult (92) 92
smoking cessation programs (91) 91
bupropion - therapeutic use (90) 90
nicotinic agonists - administration & dosage (90) 90
antihypertensive agents - adverse effects (89) 89
research (88) 88
adolescent (86) 86
quinoxalines - pharmacokinetics (84) 84
abridged index medicus (81) 81
neurosciences (80) 80
prospective studies (80) 80
psychiatry (80) 80
smoking - drug therapy (79) 79
risk factors (78) 78
drug combinations (77) 77
time factors (77) 77
tobacco use disorder - drug therapy (77) 77
nicotine (76) 76
placebo (76) 76
drug therapy (74) 74
drug administration schedule (73) 73
adrenergic alpha-agonists - adverse effects (71) 71
bupropion (69) 69
glaucoma - drug therapy (68) 68
oncology (68) 68
open-angle glaucoma (68) 68
therapy (68) 68
adrenergic alpha-agonists - therapeutic use (67) 67
mice (67) 67
antihypertensive agents - therapeutic use (66) 66
article (66) 66
care and treatment (65) 65
smoking - adverse effects (65) 65
ophthalmic solutions (64) 64
smoking prevention (62) 62
antihypertensive agents - administration & dosage (61) 61
ocular hypertension (59) 59
pharmacotherapy (59) 59
smokers (59) 59
adrenergic alpha-agonists - administration & dosage (58) 58
timolol - therapeutic use (58) 58
follow-up studies (56) 56
tobacco (55) 55
toxicology (54) 54
analysis (53) 53
randomized controlled trials as topic (53) 53
sulfonamides - therapeutic use (53) 53
cessation (52) 52
clinical trials (52) 52
health aspects (52) 52
public, environmental & occupational health (52) 52
sulfonamides - adverse effects (52) 52
medicine & public health (51) 51
sulfonamides - administration & dosage (51) 51
bupropion - adverse effects (49) 49
timolol - administration & dosage (47) 47
nicotine replacement therapy (46) 46
pharmacology/toxicology (45) 45
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1047) 1047
French (13) 13
German (10) 10
Spanish (10) 10
Russian (8) 8
Japanese (6) 6
Chinese (3) 3
Swedish (3) 3
Polish (2) 2
Romanian (2) 2
Czech (1) 1
Danish (1) 1
Dutch (1) 1
Norwegian (1) 1
Portuguese (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane Database of Systematic Reviews, ISSN 1469-493X, 05/2016, Volume 2016, Issue 5, p. CD006103
Background Nicotine receptor partial agonists may help people to stop smoking by a combination of maintaining moderate levels of dopamine to counteract... 
Smoking [drug therapy] | Varenicline | Humans | RANDOMIZED CONTROLLED-TRIAL | Quinolizines [therapeutic use] | PSYCHIATRIC ADVERSE EVENTS | TOBACCO-DEPENDENCE TREATMENT | Quinoxalines [therapeutic use] | MEDICINE, GENERAL & INTERNAL | Bupropion [therapeutic use] | Nicotine [adverse effects; antagonists & inhibitors] | REPLACEMENT THERAPY | SUSTAINED-RELEASE BUPROPION | Smoking Cessation [methods] | Counseling [methods] | VARENICLINE TREATMENT | METHADONE-MAINTAINED SMOKERS | Randomized Controlled Trials as Topic | Azepines [therapeutic use] | DOUBLE-BLIND PLACEBO | Alkaloids [therapeutic use] | Nicotinic Agonists [adverse effects; therapeutic use] | Azocines [therapeutic use] | LONG-TERM SAFETY | Benzazepines [therapeutic use] | PLACEBO-CONTROLLED TRIAL | Substance Withdrawal Syndrome [prevention & control] | Heterocyclic Compounds with 4 or More Rings [therapeutic use] | Quinolizines - therapeutic use | Azepines - adverse effects | Azocines - therapeutic use | Azocines - adverse effects | Substance Withdrawal Syndrome - prevention & control | Alkaloids - adverse effects | Benzazepines - adverse effects | Smoking - drug therapy | Heterocyclic Compounds, 4 or More Rings - adverse effects | Nicotinic Agonists - therapeutic use | Nicotine - antagonists & inhibitors | Smoking Cessation - methods | Azepines - therapeutic use | Nicotine - adverse effects | Nicotinic Agonists - adverse effects | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Benzazepines - therapeutic use | Counseling - methods | Alkaloids - therapeutic use | Quinolizines - adverse effects | Varenicline - therapeutic use | Bupropion - therapeutic use
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2017, Volume 67, Issue 2, pp. 263 - 271
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 07/2015, Volume 163, Issue 1, pp. 1 - 13
Journal Article
Journal Article
Expert Review of Anti-Infective Therapy, ISSN 1478-7210, 2014, Volume 12, Issue 7, pp. 763 - 773
About 2% of the world's population is estimated to be chronically infected with hepatitis C virus (HCV). These chronic carriers are at risk of developing liver... 
Daclatasvir | MK-8742 | Ombitasvir | Interferon-free | Ledipasvir | MK-5172 | Asunaprevir | ABT-450 | Sofosbuvir | Dasabuvir | CONTROLLED-TRIAL | PLUS RIBAVIRIN | LIVER-TRANSPLANTATION | ombitasvir | asunaprevir | HCV INFECTION | daclatasvir | interferon-free | ledipasvir | sofosbuvir | SUSTAINED VIROLOGICAL RESPONSE | PROTEASE INHIBITOR | TREATMENT OPTIONS | GENOTYPE 1 INFECTION | PHARMACOLOGY & PHARMACY | dasabuvir | CHRONIC VIRAL-HEPATITIS | DISEASE PROGRESSION | Uridine Monophosphate - administration & dosage | Quinoxalines - adverse effects | Anilides - therapeutic use | Isoquinolines - adverse effects | Hepatitis C - drug therapy | Anilides - adverse effects | Humans | Imidazoles - administration & dosage | Benzofurans - administration & dosage | Carbamates - administration & dosage | Uracil - administration & dosage | Ribavirin - administration & dosage | Uridine Monophosphate - adverse effects | Imidazoles - therapeutic use | Hepatitis C - prevention & control | Quinoxalines - therapeutic use | Uridine Monophosphate - therapeutic use | Disease Eradication | Benzofurans - therapeutic use | Quinoxalines - administration & dosage | Antiviral Agents - therapeutic use | Imidazoles - adverse effects | Ribavirin - therapeutic use | Uracil - therapeutic use | Clinical Trials as Topic | Macrocyclic Compounds - adverse effects | Antiviral Agents - administration & dosage | Benzofurans - adverse effects | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Anilides - administration & dosage | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Isoquinolines - therapeutic use | Sulfonamides - adverse effects | Carbamates - adverse effects | Macrocyclic Compounds - administration & dosage | Carbamates - therapeutic use | Hepacivirus | Isoquinolines - administration & dosage | Drug Combinations | Sulfonamides - administration & dosage | Uracil - analogs & derivatives
Journal Article
Circulation, ISSN 0009-7322, 01/2014, Volume 129, Issue 1, pp. 28 - 41
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 11/2016, Volume 165, Issue 9, pp. 625 - 634
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 15, pp. 1448 - 1455
In this uncontrolled trial involving 104 patients with hepatitis C virus infection and stage 4 or 5 kidney disease, treatment with glecaprevir and pibrentasvir... 
MEDICINE, GENERAL & INTERNAL | EFFICACY | SAFETY | SOFOSBUVIR | C VIRUS-INFECTION |